"Glycosides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Any compound that contains a constituent sugar, in which the hydroxyl group attached to the first carbon is substituted by an alcoholic, phenolic, or other group. They are named specifically for the sugar contained, such as glucoside (glucose), pentoside (pentose), fructoside (fructose), etc. Upon hydrolysis, a sugar and nonsugar component (aglycone) are formed. (From Dorland, 28th ed; From Miall's Dictionary of Chemistry, 5th ed)
| Descriptor ID |
D006027
|
| MeSH Number(s) |
D09.408
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Glycosides".
Below are MeSH descriptors whose meaning is more specific than "Glycosides".
This graph shows the total number of publications written about "Glycosides" by people in this website by year, and whether "Glycosides" was a major or minor topic of these publications.
View timeline visualization
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 1 | 2 |
| 1996 | 1 | 2 | 3 |
| 1998 | 2 | 1 | 3 |
| 1999 | 1 | 1 | 2 |
| 2000 | 3 | 1 | 4 |
| 2001 | 6 | 0 | 6 |
| 2002 | 4 | 1 | 5 |
| 2003 | 1 | 4 | 5 |
| 2004 | 2 | 0 | 2 |
| 2005 | 4 | 1 | 5 |
| 2006 | 2 | 1 | 3 |
| 2007 | 4 | 0 | 4 |
| 2008 | 3 | 1 | 4 |
| 2009 | 3 | 0 | 3 |
| 2010 | 4 | 2 | 6 |
| 2011 | 1 | 1 | 2 |
| 2012 | 1 | 3 | 4 |
| 2013 | 2 | 0 | 2 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 1 | 2 |
| 2017 | 2 | 1 | 3 |
| 2018 | 4 | 2 | 6 |
| 2019 | 8 | 1 | 9 |
| 2020 | 5 | 3 | 8 |
| 2021 | 2 | 1 | 3 |
| 2022 | 1 | 1 | 2 |
| 2023 | 1 | 3 | 4 |
| 2024 | 6 | 1 | 7 |
Below are the most recent publications written about "Glycosides" by people in Profiles.
-
How adoption of new pharmaceuticals can impact US health system reimbursement under alternative payment models: An economic model measuring the impact of sotagliflozin among patients with heart failure and diabetes. J Manag Care Spec Pharm. 2024 Aug; 30(8):843-853.
-
Pharmacokinetic evaluation of ibrexafungerp for the treatment of vulvovaginal candidiasis and beyond. Expert Opin Drug Metab Toxicol. 2024 Aug; 20(8):713-718.
-
Cost-effectiveness of sotagliflozin for the treatment of patients with diabetes and recent worsening heart failure. J Comp Eff Res. 2024 06; 13(6):e230190.
-
Beta-Hydroxybutyrate Levels and Risk of Diabetic Ketoacidosis in Adults with Type 1 Diabetes Treated with Sotagliflozin. Diabetes Technol Ther. 2024 Sep; 26(9):618-625.
-
Discovery of Potent Glycosidases Enables Quantification of Smoke-Derived Phenolic Glycosides through Enzymatic Hydrolysis. J Agric Food Chem. 2024 May 22; 72(20):11617-11628.
-
Time to clinical benefit with sotagliflozin in patients with type 2 diabetes and chronic kidney disease: Insights from the SCORED randomized trial. Eur J Heart Fail. 2024 Apr; 26(4):1093-1095.
-
Ibrexafungerp is efficacious in a neutropenic murine model of pulmonary mucormycosis as monotherapy and combined with liposomal amphotericin B. Antimicrob Agents Chemother. 2024 May 02; 68(5):e0154523.
-
Sotagliflozin Efficacy Irrespective of Hemoglobin A1c Level. J Am Coll Cardiol. 2023 11 07; 82(19):1852-1853.
-
Exploring the antiviral potential of justicidin B and four glycosylated lignans from Phyllanthus brasiliensis against Zika virus: A promising pharmacological approach. Phytomedicine. 2024 Jan; 123:155197.
-
Alternative Identification of Glycosides Using MS/MS Matching with an In Silico-Modified Aglycone Mass Spectra Library. Anal Chem. 2023 07 18; 95(28):10618-10624.